Mahendra Narendran (he/him) is a Infectious Disease Doctor, Internist in Statesville, NC with over 17 years of experience. What is your opinion of Mahendra Narendran? Rate this provider below so other people can make informed decision.
Gender
Male
Experience
Over 17 Years of Experience
Languages Spoken
English
Accepted Insurances
Medicare
Payments Received
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Mahendra Narendran has received over $13,070 which includes payments from the following companies:
$1,693.73 from Novo Nordisk Inc
$1,207.03 from AstraZeneca Pharmaceuticals LP
$1,204.91 from Pfizer Inc.
$760.11 from Janssen Pharmaceuticals, Inc
$756.55 from sanofi-aventis U.S. LLC
$709.14 from Amgen Inc.
$637.66 from Boehringer Ingelheim Pharmaceuticals, Inc.
$578.68 from Astellas Pharma US Inc
$498.61 from LILLY USA, LLC
$442.86 from Merck Sharp & Dohme Corporation
$440.21 from GlaxoSmithKline, LLC.
$407.06 from Sunovion Pharmaceuticals Inc.
$335.49 from Kowa Pharmaceuticals America, Inc.
$317.35 from Takeda Pharmaceuticals America, Inc.
$313.90 from Amarin Pharma Inc.
$312.30 from Allergan Inc.
$273.02 from Novartis Pharmaceuticals Corporation
$245.10 from Takeda Pharmaceuticals U.S.A., Inc.
$229.56 from Mylan Specialty L.P.
$177.47 from Salix Pharmaceuticals, a division of Bausch Health US, LLC
Payments received by Mahendra Narendran were from the following categories:
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!